GLP-1 Peptide Atlas, by Delfa

CompletedPhase 3Results posted

Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity

Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Asians With Obesity Diagnosed as BMI ≥ 25 kg/m2 According to Local Guidelines

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

150

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥25

Primary endpoints

•Body weight, % change•≥5% weight-loss responders

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04998136

Org study IDNN9536-4707

Secondary IDU1111-1265-5285World Health Organization (WHO)

Timeline

Milestones

Study first posted2021-08-10actual

Study start2022-08-15actual

Primary completion2023-10-16actual

Study completion2023-11-20actual

Results first posted2025-04-03actual

Last update posted2025-12-30actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Age above or equal to 18 years at the time of signing informed consent.

•BMI at least 25.0 kg/m^2 at screening.

•Both parents of Asian descent.

•History of at least one self-reported unsuccessful dietary effort to lose body weight.

Exclusion criteria

•HbA1c at least 48 mmol/mol (6.5%) as measured by the central laboratory at screening.

•History of type 1 or type 2 diabetes mellitus.

•A self-reported change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records.

•Any participant where a substantial weight loss, in the investigator's opinion, might jeopardise the participant's safety.

•Renal impairment with estimated Glomerular Filtration Rate (eGFR) below 15 mL/min/1.73 m^2 at screening.

Endpoints (46)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Weight & body composition

Glycemic / diabetes

Weight & body composition

20 endpoints

Primary/registry result

Change in Body Weight (%) : In-trial Observation Period

Time frame:Baseline (week 0), end of treatment (week 44)

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (mean), Percentage of body weight	95% CI
Semaglutide	-16.4	—
Placebo	-2.6	—

Treatment difference-12.9995% CI-15.28 – -10.70p<0.0001ANCOVA

Primary/registry result

Change in Body Weight (%) : On-treatment Observation Period

Time frame:Baseline (week 0), end of treatment (week 44)

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (mean), Percentage of body weight	95% CI
Semaglutide	-16.4	—
Placebo	-2.7	—

Treatment Difference-13.4095% CI-15.70 – -11.11p<0.0001MMRM

Primary/registry result

Number of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : In-trial Observation Period

Time frame:At week 44

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
SemaglutideYes	96	—
No	4	—
PlaceboYes	12	—
No	36	—

Odds Ratio (OR)88.8795% CI21.96 – 359.61p<0.0001Regression, Logistic

Primary/registry result

Number of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : On-treatment Observation Period

Time frame:At week 44

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
SemaglutideYes	92	—
No	4	—
PlaceboYes	12	—
No	35	—

Odds Ratio (OR)253.4795% CI38.41 – 1672.57p<0.0001Regression, Logistic

Primary/protocol endpoint

Change in Body Weight (%) : In-trial Observation Period

Time frame:Baseline (week 0), end of treatment (week 44)

Body weight, % change

percent change from baseline, improvement

Primary/protocol endpoint

Change in Body Weight (%) : On-treatment Observation Period

Time frame:Baseline (week 0), end of treatment (week 44)

Body weight, % change

percent change from baseline, improvement

Primary/protocol endpoint

Number of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : In-trial Observation Period

Time frame:At week 44

≥5% weight-loss responders

threshold achievement, improvement

Primary/protocol endpoint

Number of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : On-treatment Observation Period

Time frame:At week 44

≥5% weight-loss responders

threshold achievement, improvement

Secondary/registry result

Number of Participants Achieved ≥ 10% Body Weight Reduction (Yes/no)

Time frame:At week 44

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
SemaglutideYes	78	—
No	22	—
PlaceboYes	5	—
No	43	—

Secondary/registry result

Number of Participants Achieved ≥15% Body Weight Reduction (Yes/no)

Time frame:At week 44

≥15% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
SemaglutideYes	53	—
No	47	—
PlaceboYes	2	—
No	46	—

Secondary/registry result

Number of Participants Achieved ≥20% Body Weight Reduction (Yes/no)

Time frame:At week 44

≥20% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
SemaglutideYes	30	—
No	70	—
PlaceboYes	0	—
No	48	—

Secondary/registry result

Change in Waist Circumference

Time frame:Baseline (week 0), end of treatment (week 44)

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (mean), Centimeter (cm)	95% CI
Semaglutide	-12.0	—
Placebo	-3.0	—

Secondary/registry result

Change in Body Weight (kg)

Time frame:Baseline (week 0), end of treatment (week 44)

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (mean), Kg	95% CI
Semaglutide	-13.0	—
Placebo	-2.0	—

Secondary/registry result

Change in Body Mass Index

Time frame:Baseline (week 0), end of treatment (week 44)

BMI, change

change from baseline, improvement

Posted result

Group	Value (mean), Kilogram per square meter (kg/m^2)	95% CI
Semaglutide	-4.9	—
Placebo	-0.8	—

Secondary/protocol endpoint

Number of Participants Achieved ≥ 10% Body Weight Reduction (Yes/no)

Time frame:At week 44

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Number of Participants Achieved ≥15% Body Weight Reduction (Yes/no)

Time frame:At week 44

≥15% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Number of Participants Achieved ≥20% Body Weight Reduction (Yes/no)

Time frame:At week 44

≥20% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Change in Waist Circumference

Time frame:Baseline (week 0), end of treatment (week 44)

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Weight (kg)

Time frame:Baseline (week 0), end of treatment (week 44)

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Mass Index

Time frame:Baseline (week 0), end of treatment (week 44)

BMI, change

change from baseline, improvement

Glycemic / diabetes

4 endpoints

Secondary/registry result

Change in HbA1c (%)

Time frame:Baseline (week 0), end of treatment (week 44)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (mean), Percentage of HbA1c	95% CI
Semaglutide	-0.4	—
Placebo	0.0	—

Secondary/registry result

Change in HbA1c (mmol/Mol)

Time frame:Baseline (week 0), end of treatment (week 44)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (mean), Mmol/mol	95% CI
Semaglutide	-4.5	—
Placebo	-0.1	—

Secondary/protocol endpoint

Change in HbA1c (%)

Time frame:Baseline (week 0), end of treatment (week 44)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c (mmol/Mol)

Time frame:Baseline (week 0), end of treatment (week 44)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Cardiometabolic biomarkers

22 endpoints

Secondary/registry result

Change in Systolic Blood Pressure (mmHg)

Time frame:Baseline (week 0), end of treatment (week 44)

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Posted result

Group	Value (mean), Millimeter of mercury (mmHg)	95% CI
Semaglutide	-11	—
Placebo	-1	—

Secondary/registry result

Change in Diastolic Blood Pressure

Time frame:Baseline (week 0), end of treatment (week 44)

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Posted result

Group	Value (mean), MmHg	95% CI
Semaglutide	-4	—
Placebo	0	—

Secondary/registry result

Change in Total Cholesterol (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Posted result

Group	Value (geometric_mean), Ratio of total cholesterol	95% CI
Semaglutide	0.91	—
Placebo	1.03	—

Secondary/registry result

Change in Total Cholesterol (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Posted result

Group	Value (geometric_mean), Ratio of total cholesterol	95% CI
Semaglutide	0.91	—
Placebo	1.03	—

Secondary/registry result

Change in High-density Lipoprotein (HDL) Cholesterol (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

HDL-C, change

ratio, improvement

LOINC 2085-9

Posted result

Group	Value (geometric_mean), Ratio of HDL cholesterol	95% CI
Semaglutide	1.00	—
Placebo	1.04	—

Secondary/registry result

Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

HDL-C, change

ratio, improvement

LOINC 2085-9

Posted result

Group	Value (geometric_mean), Ratio of HDL cholesterol	95% CI
Semaglutide	1.00	—
Placebo	1.04	—

Secondary/registry result

Change in Low-density Lipoprotein (LDL) Cholesterol (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

LDL-C, change

ratio, improvement

LOINC 13457-7

Posted result

Group	Value (geometric_mean), Ratio of LDL cholesterol	95% CI
Semaglutide	0.93	—
Placebo	1.04	—

Secondary/registry result

Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

LDL-C, change

ratio, improvement

LOINC 13457-7

Posted result

Group	Value (geometric_mean), Ratio of LDL cholesterol	95% CI
Semaglutide	0.93	—
Placebo	1.04	—

Secondary/registry result

Change in Triglycerides (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

Triglycerides, change

ratio, improvement

LOINC 2571-8

Posted result

Group	Value (geometric_mean), Ratio of triglycerides	95% CI
Semaglutide	0.72	—
Placebo	0.96	—

Secondary/registry result

Change in Triglycerides (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

Triglycerides, change

ratio, improvement

LOINC 2571-8

Posted result

Group	Value (geometric_mean), Ratio of triglycerides	95% CI
Semaglutide	0.72	—
Placebo	0.96	—

Secondary/registry result

Change in High-sensitivity C-reactive Protein (hsCRP) (mg/L) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

hs-CRP, change

ratio, improvement

LOINC 30522-7

Posted result

Group	Value (geometric_mean), Ratio of hsCRP	95% CI
Semaglutide	0.54	—
Placebo	0.89	—

Secondary/protocol endpoint

Change in Systolic Blood Pressure (mmHg)

Time frame:Baseline (week 0), end of treatment (week 44)

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change in Diastolic Blood Pressure

Time frame:Baseline (week 0), end of treatment (week 44)

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Secondary/protocol endpoint

Change in Total Cholesterol (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change in Total Cholesterol (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change in High-density Lipoprotein (HDL) Cholesterol (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

HDL-C, change

ratio, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

HDL-C, change

ratio, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in Low-density Lipoprotein (LDL) Cholesterol (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

LDL-C, change

ratio, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

LDL-C, change

ratio, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in Triglycerides (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

Triglycerides, change

ratio, improvement

Secondary/protocol endpoint

Change in Triglycerides (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

Triglycerides, change

ratio, improvement

Secondary/protocol endpoint

Change in High-sensitivity C-reactive Protein (hsCRP) (mg/L) - Ratio to Baseline

Time frame:Baseline (week 0), end of treatment (week 44)

hs-CRP, change

ratio, improvement

LOINC 30522-7

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m(2), in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.
The lancet. Diabetes & endocrinology2025 Oct (month)PMID40825340doi:10.1016/S2213-8587(25)00164-0via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.